A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia

BACKGROUND: The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Fields, T., Patterson, M., Bremova-Ertl, T., Belcher, G., Billington, I., Churchill, G. C., Davis, W., Evans, W., Flint, S., Galione, A., Granzer, U., Greenfield, J., Karl, R., Kay, R., Lewi, D., Mathieson, T., Meyer, T., Pangonis, D., Platt, F. M., Tsang, L., Verburg, C., Factor, M., Strupp, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821839/
https://www.ncbi.nlm.nih.gov/pubmed/33482890
http://dx.doi.org/10.1186/s13063-020-05009-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821839/
https://www.ncbi.nlm.nih.gov/pubmed/33482890
http://dx.doi.org/10.1186/s13063-020-05009-3

Ejemplares similares